Abbott’s Wallis trial
This article was originally published in The Gray Sheet
Executive Summary
First subject implanted in the U.S. with the firm's Wallis dynamic stabilization spinal implant to treat degenerative disc disease as part of a 340-patient, 20-center clinical trial to support PMA approval. Unlike total disc replacement, such as Johnson & Johnson's Charité, the device does not require an abdominal insertion and does not replace the disc but instead re-routes spinal load through the use of spacers. Abbott acquired Wallis developer Spine Next for $60 mil. in 2004 (1"The Gray Sheet" Nov. 1, 2004, p. 5)...
You may also be interested in...
Nonfusion Alternative To Artificial Discs Acquired By Abbott/Spinal Concepts
Abbott Labs will launch a clinical trial early next year supporting a PMA submission for Spine Next's Wallis nonfusion spine stabilization device, having acquired the French manufacturer for $60 mil. and potential milestone payments
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.